600671 ST天目药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-66.340-339.450-441.328-50.499-46.400
总资产报酬率 ROA (%)-5.446-11.798-19.148-7.052-8.359
投入资产回报率 ROIC (%)-12.949-28.512-49.337-16.531-24.847

边际利润分析
销售毛利率 (%)27.02021.78722.93431.22438.803
营业利润率 (%)-41.053-30.851-64.168-25.840-27.444
息税前利润/营业总收入 (%)-28.752-23.961-59.650-17.903-21.064
净利润/营业总收入 (%)-31.716-32.268-67.143-22.290-24.948

收益指标分析
经营活动净收益/利润总额(%)117.04081.95350.76081.05830.241
价值变动净收益/利润总额(%)-0.1351.448-1.3330.000-0.141
营业外收支净额/利润总额(%)-14.332-3.4683.431-12.650-12.037

偿债能力分析
流动比率 (X)0.7400.8240.5610.7410.885
速动比率 (X)0.5050.6290.3460.5320.617
资产负债率 (%)87.65383.84398.49383.96778.908
带息债务/全部投入资本 (%)33.25132.81442.97819.740--
股东权益/带息债务 (%)44.36670.998-31.116139.042282.351
股东权益/负债合计 (%)6.38212.791-4.89513.36420.861
利息保障倍数 (X)-4.019-4.092-8.776-3.556-6.138

营运能力分析
应收账款周转天数 (天)103.01099.756135.909116.6370.000
存货周转天数 (天)199.149171.044214.290213.3150.000